The Safety of Edaravone for patients with Amyotrophic Lateral Sclerosis: Single centered open label trial

The Safety of Edaravone for patients with Amyotrophic Lateral Sclerosis: Single centered open label trial - The Safety of Edaravone for patients with Amyotrophic Lateral Sclerosis

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016352

Enrollment

Registered

2015-02-01

Start date

2015-02-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

amyotrophic lateral sclerosis

Interventions

edaravone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: Severe kidney failure Past history with hyper-reaction against Edaravone Physician's opinion against participation

Design outcomes

Primary

Measure	Time frame
Adverse effects leading discontinuation of the medication	—

Secondary

Measure	Time frame
1. Respiratory volume 2. ALSFRS: Amyotrophic Lateral Screlosis Functional Rating Scale	—

Countries

Japan

Contacts

Public ContactHirotaka Iwaki

Ehime University Hospital Clinical neurology and pharmacology

h-iwaki@m.ehime-u.ac.jp0899605095

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026